Shire has acquired Meritage for an upfront fee of $70 million and additional contingent payments based on the achievement of development and regulatory milestones.
With the acquisition, Shire has acquired the global rights to-and undertaken the further development of-Meritage's Phase 3-ready compound, Oral Budesonide Suspension (OBS), for the treatment of adolescents and adults with eosinophilic esophagitis (EoE), a rare, chronic inflammatory gastrointestinal (GI) disease.
|Searching for more deal information? Current Partnering offers the following options:
This acquisition further enhances Shire's late-stage pipeline and builds upon the Company's rare disease and GI commercial infrastructure and expertise.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies